Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma

World Journal of Urology

Volumn 18, Issue 3, 2000, Pages 216-221

  Walther, Philip J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

HUMAN; MALE; PROSTATE TUMOR; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0034207955     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450000126     Document Type: Article

References (53)

1. Brenkman WD Jr, Lastinger L, Sedar F (1981) Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer. JAMA 245: 2501-2504
2. Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med 5: 280-285
3. Dawson NA (1999) Response criteria in prostatic carcinoma. SeminOncol 26: 174-184
4. Dexeus F, Logothetis CJ, Samuels ML, Hossan E, Von Eschenbach AC (1985) Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 69: 885-886
5. Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, Tkaczuk K.H, Lowitt MH, Hemady RK, Jacobs SC, et al (1995) Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13: 2174, -2186
6. Figg WD, Bergan R, Brawley O, et al (1997) Randomized phase II study of thalidomide in androgen-independent prostate cancer. Proc Am Soc Clin Oncol 16: 1189
7. Haas N, Garay C, Roth B, Babb J, Rogatko A, Entmacher M, Weinstein A, Minitti C, Finch D, Yeslow G, Gillon T, Hudes G (1999) Weekly paclitaxel by 3-hour infusion plus oral estramustine in metastatic hormone refractory prostate cancer. Proc Am Soc Clin Oncol 18: 340A
8. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K, Comis R (1992) Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-1761
9. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roeihke S. McAleer C (1997) Phase II trial of 96-hour paclitaxcl plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3156 3163
10. Hucies G, Einhorn L, Ross E, Balsham A. Loehrer P. Ramscy H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F. Hanna M. Roth B (1999) Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17: 3160 3166
11. Jungi WF, Bernhard J. Hurny C, Schmilz SF. Sanselmann S. Gusset H. Pestalozzi D, Goldhirsch A (1998) Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 6: 462-468
12. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17: 2506 2613
13. Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI (1995) Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13: 2208-2213
14. Ko UJ, Chachoua A, Small E, Reese D, Kabbinavar F, Taneja S, DePaoli A. Hannah A, Balk S, Bubley G (1999) Phase II study of SU 101 in patients with PSA-positive prostate cancer. Proc Am Soc Clin Oncol 18: 317A
15. Kreis W. Budman DR, Fetten J. Gonzales AL, Barile B. Vinciguerra V (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10: 33 38
16. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P. Andre S (1995) Preclinical evaluation of docetaxel. Semin Oncol 22 [SuppU]: 3-16
17. Mahjoubi M, Azab M, Ghosn M, Theodore C, Droz JP (2000) Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer. Cancer Invest 8: 477-481
18. Melnyk O, Zimmerman M, Kim KJ, Shuman M (1999) Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and métastases in a pre-clinical model. J Urol 161: 960-963
19. Moore MR. Trôner MB, DeSimone P, Birch R, Irwin L (1986) Phase II evaluation of weekly cisplatin in metastatic hormone resistant prostate cancer: a Southeastern Cancer Study Group trial. Cancer 70: 541-543
20. Moore MR, Graham SD, Birch R, Irwin L (1987) Phase II evaluation of mitoguazone in metastatic hormone resistant prostate cancer: a Southeastern Cancer Group trial. Cancer Treat Rep 71: 89-90
21. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G. Choyke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan WM (1992) Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10: 881-889
22. Natale RB, Zaretsky SL (1999) Phase I/II trial of estramustine and Taxotere in patients with metastatic hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 18: 348A
23. Nogueira-Costa R, Ramos LAG, Duarte RC, Chiari AP (1999) Oral cyclophosphamide for chemotherapy-naive hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 18: 349A
24. Oudard S. Carles J, Tresca P, Brandely M, Favreau E (1999) Navelbine single agent or in combination as first line chemotherapy in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 18: 321A
25. Paulson DF, Berry WR, Cox EB, Walker A, Laszlo J (1979) Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. J Natl Cancer Inst 63: 615-622
26. Petrylak DP. Macarthur RB. O'Connor J, Shelton G, Judge T. Balog J. Pfaff C, Bagiella E, Heitjan D, Fine R. Zuech N, Sawczuk I, Benson M. Olsson CA (1999) Phase I trial of docctaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17: 958-967
27. Picus J, Schultz M. Cochrane J (1999) A phase II trial of docelaxel in patients with hormone refractory prostate cancer: long term results. Proc Am Soc Clin Oncol 18: 314A
28. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Espcr PS, Naik H. Smith DC (1997) A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50: 401-4(16
29. Raghavan D. Cox K. Pearson BS. Coorey GJ, Rogers J. Watt WH, Coates AS. McNeil E. Grygial JJ (1993) Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 72: 625-628
30. Reese D. Fröhlich M. Bok R, Corry M. Novotny W. Homgren E. Small E (1999) A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 18: 351A
31. Roth BJ. Yeap BY. Wilding G. Kasimis B, McLeod D, Loehrer PJ (1993) Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72: 2457-2460
32. Savarese DM. Taplin M-E, Marchesani B, Kreis W, Akerley WL. Godley PA. Halabi S, Vogelzang NJ (1999) A phase II study of docetaxel, estramustine. and low dose hydrocortisone in hormone refractory prostate cancer: CALGB 9780. Proc Am Soc Clin Oncol 18: 321A
33. Scher HI. Yagoda A. Watson RC, Serber M, Whitmore W (1984) Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131: 1099-1102
34. Scher HI, Curley T. Geller N, Dershaw D, Chan E. Nisselbaum J. Alcock N. Hollander P. Yagoda A (1987) Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover. Cancer Treat Rep 71: 887-893
35. Scher HI, Curley T. Geller N, Engstrom C, Dershaw DD, Lin SY. Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L. et al (1990) Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8: 1830-1838
36. Scher HI. Steineck G. Kelly WK (1995) Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46: 142 148
37. Scher HI. Kelly WM. Zhang ZF, Ouyang P, Sun M, Schwartz M. Ding C. Wang W, Horak ID, Kremer AB (1999) Posttherapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91: 244 251
38. Schröder FH, EORTC Urological Group (1984) Treatment response criteria for prostate cancer. Prostate 5: 181-191
39. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T (1992) Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. .1 Urol 147: 931-934
40. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ (1994) Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgenindependent prostate cancer. J Clin Oncol 12: 683-688
41. Sinibaldi VJ. Carducci MA, Moore-Cooper S, Enger C, Läufer M, Wolff AC, Eisenberger MA (1999) A phase II study evaluating a one day course of estramustine phosphate and docetaxel in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 18: 322A
42. Smith DC, Vogelzang NJ, Goldberg HL, et al (1993) Highdose cyclophosphamide with granulocyte-macrophage-colony stimulating factor (GM-CSF) in hormone refractory prostate cancer (abstract). Proc Am Soc Clin Oncol 11: 213
43. Smith DC. Esper P, Strawderman M, Redman B, Pienta KJ (1999) Phase II trial of oral estramustine, oral etoposide. and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17: 1664-1671
44. Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13: 2944-2953
45. Steineck G, Kelly WK. Mazumdar M, Vlamis V, Schwartz M, Scher HI (1996) Acid phosphatase: defining a role in androgenindependent prostate cancer. Urology 47: 719-726
46. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL (1995) Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76: 96-100
47. Taneja S, Chachoua A, Ferrari A, Utate M, Kutz L, Stone N. Stock R, Baldwin Y, Lepor H, Muggia F (1999) Phase I trial of Taxol/estramustine in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 18: 354A
48. Tannock IF (1985) Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3: 1013-1021
49. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ. Venner PM, Coppin CM. Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1753-1755
50. Weitzman A, Shelton G. Zuech N, England-Owen C, Newhouse J, Bagiella E. Katz A, Sawczuk I, Bensoln M, Olsson C. Petrylak DP (1999) Phase II study of estramustine combined with docetaxel in patients with androgen-independent prostate cancer. Proc Am Soc Clin Oncol 18: 355A
51. Williamson SK, A'Hern R, Wolf MK, Eisenberger MA, O'Rourke MA, Brannon W, Crawford ED (1996) Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Am J Clin Oncol 19:368 370
52. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71: 1098-1109
53. Yagoda A, Watson RC, Barzell WE, Sogani P, Grabstald H, Whitmore WF (1979) A critical analysis of response criteria in patients with prostate cancer treated with cw-diamminedichloride platinum (II). Cancer 44: 1563- 1566